Ozempic, Wegovy, and Mounjaro have transformed how medicine treats obesity and type 2 diabetes. Tens of millions of Americans are now on GLP-1 receptor agonists, and that number is growing fast. But there is a problem that does not get discussed enough in the coverage of this pharmaceutical revolution: a significant proportion of patients stop taking these drugs because they cannot tolerate the nausea and vomiting. On April 8, 2026, Vanda Pharmaceuticals (NASDAQ: VNDA) announced the initiation of the Thetis clinical trial, evaluating its FDA-approved drug NEREUS (tradipitant) specifically for the prevention of vomiting in patients taking GLP-1 therapies. Topline results are expected by Q4 2026.
The Phase 2 data that got this trial started is compelling. In an earlier study, only 29.3% of patients taking tradipitant experienced vomiting, compared to 58.6% on placebo. That is a 50% relative reduction.
Why GLP-1 side effects are a bigger clinical problem than headlines suggest
GLP-1 receptor agonists work partly by slowing gastric emptying and suppressing appetite through signals in the gut and brain. Those same mechanisms produce nausea and vomiting in a substantial subset of patients, particularly at higher doses. The FDA approved a higher dose of Wegovy last month specifically because it delivers additional weight-loss benefit, but the two most common adverse effects at that dose, nausea and vomiting, occur at increased frequency compared to the previously approved maximum dose.
That tradeoff is a genuine clinical dilemma. The drugs that work best at producing weight loss are also the drugs most likely to make patients feel sick enough to stop taking them. Treatment discontinuation and dose reduction due to gastrointestinal side effects are consistently among the most frequently cited reasons patients do not achieve the full benefit of GLP-1 therapy.
According to JAMA Internal Medicine’s research on GLP-1 adherence, medication persistence at 12 months for GLP-1 receptor agonists in real-world settings is significantly lower than in clinical trials, with gastrointestinal side effects cited as the primary driver of discontinuation. Given that these drugs typically require sustained use to maintain weight loss benefits, discontinuation represents a significant clinical failure even when the drug itself works.
What tradipitant is and why it was a logical candidate for this problem
Tradipitant is a neurokinin-1 receptor antagonist. NK-1 receptors are involved in the vomiting reflex, and drugs that block them have been used in chemotherapy-induced nausea and vomiting for decades. Tradipitant’s mechanism is directly relevant to GLP-1 induced vomiting because the same neural pathways activated by GLP-1 drugs overlap significantly with those that NK-1 antagonists suppress.
NEREUS is already FDA-approved for the prevention of vomiting induced by motion sickness in adults, providing a validated safety and efficacy baseline in a real-world approved indication. That existing approval matters for the GLP-1 program because it means the drug’s basic safety profile is already established in an approved population. The question the Thetis trial is designed to answer is whether that efficacy translates to GLP-1 patients at scale.
The Phase 2 study design was particularly rigorous. Patients were given a 1mg injection of Wegovy, a dose that normally requires nine weeks of titration to reach safely, immediately rather than gradually. That accelerated exposure is essentially a worst-case scenario for GLP-1 induced vomiting. The fact that tradipitant cut the vomiting rate in half under those conditions suggests meaningful clinical utility even in the most challenging circumstances.
The market opportunity is enormous and largely unaddressed
Approximately 15 million Americans are currently prescribed GLP-1 receptor agonists according to IQVIA’s prescription tracking data, and that number is projected to grow significantly through 2030 as new indications beyond diabetes and obesity, including cardiovascular disease, sleep apnea, and liver disease, receive approval. The addressable market for a drug that improves GLP-1 tolerability is essentially the entire GLP-1 patient population, which is one of the fastest-growing drug categories in the history of pharmaceuticals.
There is currently no FDA-approved treatment specifically indicated for GLP-1 induced nausea and vomiting. Physicians manage it with dose titration, dietary advice, and general antiemetics, none of which were designed or tested specifically for this mechanism. A drug with demonstrated Phase 2 efficacy in a randomized, double-blind, placebo-controlled trial, meeting both primary and key secondary endpoints, would be entering an unmet need with no direct competition.
The commercial logic is reinforced by the GLP-1 manufacturers’ own interest in this space. Novo Nordisk and Eli Lilly have significant financial incentives to see adherence improve. A patient who stops taking Wegovy because of vomiting is a lost customer for Novo Nordisk. A drug that keeps patients on GLP-1 therapy longer is commercially complementary to the entire GLP-1 ecosystem.
What investors should watch
The Thetis study is a multicenter, randomized, double-blind, placebo-controlled trial with a clear primary endpoint: the proportion of patients free from vomiting episodes during the treatment period. That endpoint mirrors the Phase 2 design that already demonstrated success. Topline results are expected by Q4 2026.
Replication of Phase 2 results in a larger, more diverse patient population would support a New Drug Application submission. Vanda acknowledges that additional study data may be required before NDA approval, preserving optionality for regulators to request further evidence.
Vanda is a small-cap biopharmaceutical company. Clinical trial risk is inherent at every stage, and Phase 2 success does not guarantee Phase 3 replication. Investors should evaluate this as a binary clinical catalyst story with the Q4 2026 topline readout as the critical event.
Sources
- JAMA Internal Medicine — GLP-1 Adherence Research
- IQVIA — Use of Medicines in the US 2025
- NEREUS Prescribing Information
- Vanda Pharmaceuticals — Investor Relations
Editorial disclosure
This article is based on a press release issued by Vanda Pharmaceuticals Inc. and has been independently rewritten and editorially expanded. It covers the initiation of the Thetis clinical trial evaluating NEREUS (tradipitant) for prevention of GLP-1 induced vomiting. Vanda Pharmaceuticals trades on NASDAQ under the ticker VNDA. NEREUS is FDA-approved for motion sickness vomiting prevention. Its use for GLP-1 induced vomiting is investigational and not FDA-approved. Clinical trial results are uncertain and Phase 2 success does not guarantee Phase 3 replication. This article does not constitute medical or investment advice. Market context is sourced from JAMA Internal Medicine and IQVIA. Commentary reflects the author’s own assessment. The information provided on this website is for informational and educational purposes only. Our content is derived strictly from verified online sources to ensure accuracy and objectivity. This analysis does not constitute financial, investment, or professional advice. Readers are encouraged to consult with qualified professionals before making decisions based on this information. For more information, please see our full DISCLAIMER.
